- Report
- November 2026
- 278 Pages
Global
From €5407EUR$5,850USD£4,507GBP
- Report
- November 2026
- 369 Pages
Global
From €5407EUR$5,850USD£4,507GBP
- Report
- November 2026
- 281 Pages
Global
From €5407EUR$5,850USD£4,507GBP
- Report
- November 2026
- 391 Pages
Global
From €5407EUR$5,850USD£4,507GBP
- Report
- April 2026
- 166 Pages
Global
From €7385EUR$7,990USD£6,156GBP
- Report
- September 2026
- 140 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- August 2026
- 196 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- August 2026
- 105 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- August 2026
- 120 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- July 2026
- 180 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- July 2026
- 120 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- May 2026
- 140 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- May 2026
- 140 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- January 2026
- 110 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- July 2026
- 200 Pages
Global
From €7385EUR$7,990USD£6,156GBP
- Report
- July 2026
- 110 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- July 2026
- 180 Pages
Global
From €4390EUR$4,750USD£3,660GBP
- Report
- May 2026
- 100 Pages
Global
From €2495EUR$2,699USD£2,080GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2578EUR$2,789USD£2,149GBP
- Report
- May 2026
- 400 Pages
Global
From €4574EUR$4,949USD£3,813GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more